772 related articles for article (PubMed ID: 7859456)
21. Alterations in endometrial stromal cell tissue factor protein and messenger ribonucleic acid expression in patients experiencing abnormal uterine bleeding while using Norplant-2 contraception.
Runic R; Schatz F; Krey L; Demopoulos R; Thung S; Wan L; Lockwood CJ
J Clin Endocrinol Metab; 1997 Jun; 82(6):1983-8. PubMed ID: 9177417
[TBL] [Abstract][Full Text] [Related]
22. Progesterone receptor in Norplant endometrium.
Lau TM; Witjaksono J; Rogers PA
Hum Reprod; 1996 Oct; 11 Suppl 2():90-4. PubMed ID: 8982750
[TBL] [Abstract][Full Text] [Related]
23. Morphometric study of the human endometrium following continuous exposure to levonorgestrel released from vaginal rings during 90 days.
Johannisson E; Brosens I; Cornillie F; Elder M; White J; Sheppard B; Hourihan H; d'Arcangues C; Belsey EM
Contraception; 1991 Apr; 43(4):361-74. PubMed ID: 1906792
[TBL] [Abstract][Full Text] [Related]
24. Intracervical and fundal administration of levonorgestrel for contraception: endometrial thickness, patterns of bleeding, and persisting ovarian follicles.
Pakarinen PI; Suvisaari J; Luukkainen T; Lähteenmäki P
Fertil Steril; 1997 Jul; 68(1):59-64. PubMed ID: 9207585
[TBL] [Abstract][Full Text] [Related]
25. A five-year clinical evaluation of Norplant contraceptive subdermal implants in Bangladeshi acceptors.
Akhter H; Dunson TR; Amatya RN; Begum K; Chowdhury T; Dighe N; Krueger SL; Rahman S
Contraception; 1993 Jun; 47(6):569-82. PubMed ID: 8334891
[TBL] [Abstract][Full Text] [Related]
26. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
[TBL] [Abstract][Full Text] [Related]
27. Endometrial microvascular density during the normal menstrual cycle and following exposure to long-term levonorgestrel.
Rogers PA; Au CL; Affandi B
Hum Reprod; 1993 Sep; 8(9):1396-404. PubMed ID: 8253925
[TBL] [Abstract][Full Text] [Related]
28. The effect of mefenamic acid on controlling irregular uterine bleeding secondary to Norplant use.
Kaewrudee S; Taneepanichskul S; Jaisamraun U; Reinprayoon D
Contraception; 1999 Jul; 60(1):25-30. PubMed ID: 10549449
[TBL] [Abstract][Full Text] [Related]
29. A 2-year comparative study of endometrial histology and cervical cytology of contraceptive implant users in Birmingham, UK.
Mascarenhas L; van Beek A; Bennink HC; Newton J
Hum Reprod; 1998 Nov; 13(11):3057-60. PubMed ID: 9853856
[TBL] [Abstract][Full Text] [Related]
30. Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery.
Critchley HO; Wang H; Jones RL; Kelly RW; Drudy TA; Gebbie AE; Buckley CH; McNeilly AS; Glasier AF
Hum Reprod; 1998 May; 13(5):1218-24. PubMed ID: 9647550
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate.
Landgren BM; Johannisson E; Masironi B; Diczfalusy E
Contraception; 1982 Dec; 26(6):567-85. PubMed ID: 6820337
[TBL] [Abstract][Full Text] [Related]
32. The effects of levonorgestrel implants on vascular endothelial growth factor expression in the endometrium.
Lau TM; Affandi B; Rogers PA
Mol Hum Reprod; 1999 Jan; 5(1):57-63. PubMed ID: 10050663
[TBL] [Abstract][Full Text] [Related]
33. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
Xiao B; Zeng T; Wu S; Sun H; Xiao N
Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
[TBL] [Abstract][Full Text] [Related]
34. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives.
Mainwaring R; Hales HA; Stevenson K; Hatasaka HH; Poulson AM; Jones KP; Peterson CM
Contraception; 1995 Mar; 51(3):149-53. PubMed ID: 7621683
[TBL] [Abstract][Full Text] [Related]
35. A review of the endometrial changes in Norplant users.
Wan LS
Ann N Y Acad Sci; 1997 Sep; 828():108-10. PubMed ID: 9329828
[TBL] [Abstract][Full Text] [Related]
36. Endometrial vascular features prior to and following exposure to levonorgestrel.
Hourihan HM; Sheppard BL; Belsey EM; Brosens IA
Contraception; 1991 Apr; 43(4):375-85. PubMed ID: 1906793
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of Norplant implants among Thai women in Bangkok.
Chompootaweep S; Kochagarn E; Sirisumpan S; Tang-usaha J; Theppitaksak B; Dusitsin N
Contraception; 1996 Jan; 53(1):33-6. PubMed ID: 8631187
[TBL] [Abstract][Full Text] [Related]
38. Phase III clinical trial with Norplant II (two covered rods): report on five years of use.
Contraception; 1993 Aug; 48(2):120-32. PubMed ID: 8403909
[TBL] [Abstract][Full Text] [Related]
39. Ovarian endocrine function through five years of continuous treatment with NORPLANT subdermal contraceptive implants.
Brache V; Alvarez-Sanchez F; Faundes A; Tejada AS; Cochon L
Contraception; 1990 Feb; 41(2):169-77. PubMed ID: 2107058
[TBL] [Abstract][Full Text] [Related]
40. The effect of RU486 administered during the proliferative and secretory phase of the cycle on the bleeding pattern, hormonal parameters and the endometrium.
Swahn ML; Johannisson E; Daniore V; de la Torre B; Bygdeman M
Hum Reprod; 1988 Oct; 3(7):915-21. PubMed ID: 2846630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
